The global cholesterol testing services market is valued at $25.5 billion in 2026 and is projected to reach $44.2 billion by 2034, expanding at a 7.4% compound annual growth rate. Growth is being supported by cardiovascular disease awareness, preventive screening, chronic disease management and healthcare initiatives focused on earlier detection and sustained lipid control. Retail pharmacies, point-of-care testing, home sample collection, digital result delivery and preventive health platforms are broadening access. Providers are also competing on testing quality, reliability, turnaround times, follow-up services, partnerships and operational efficiency. North America and Europe remain major markets, while urban Asia-Pacific is gaining momentum and opportunities in the Middle East, Africa, South America and Central America are linked to healthcare investment and improved diagnostic access. Price sensitivity, reimbursement differences, regulatory requirements and competition from consumer wellness alternatives remain important commercial factors. The ResearchAndMarkets.com report covers 2026-2034 using Porter's Five Forces, value-chain mapping, supply-and-demand analysis, trade intelligence and scenario-based forecasting.